EFFECT OF INTRAVENOUS METOPROLOL TARTRATE ON MORTALITY IN PATIENTS WITH SEPTIC SHOCK DUE TO VENTILATOR-ASSOCIATED PNEUMONIA. | ||
| ALEXMED ePosters | ||
| Article 1, Volume 6, Issue 4, September 2024, Pages 19-20 | ||
| Document Type: Preliminary preprint short reports of original research | ||
| DOI: 10.21608/alexpo.2024.324109.1952 | ||
| Authors | ||
| Akram Muhammad Fayed; Haytham Saber Meligy; Sherouk Rafik Abdelrahman Abu Elnasser Hamad* | ||
| Department of Critical Care Medicine, Faculty of Medicine, Alexandria University | ||
| Abstract | ||
| Tachycardia is a critical issue in septic shock, as it increases myocardial oxygen demand and worsens cardiovascular function. This elevated heart rate, driven by excessive sympathetic activation, persists despite addressing underlying causes and is associated with increased catecholamine levels, myocardial dysfunction, and vascular hyporeactivity. Prolonged exposure to high catecholamine levels can lead to detrimental effects, including myocardial damage, insulin resistance, thrombogenicity, immune suppression, and bacterial growth. β-Adrenergic blockers have emerged as a potential therapy to manage heart rate and counteract these harmful effects by offering neurohormonal protection. Preclinical studies show that β-blockers, particularly when administered before sepsis onset, improve outcomes. Although concerns exist about cardiovascular collapse with β-blockers in septic shock, research supports their safety, especially with oral metoprolol and intravenous esmolol. AIMOF THE WORK: This study aims to evaluate whether intravenous β-blockers, particularly metoprolol, can reduce 28-day mortality in septic shock patients by effectively lowering heart rates and improving hemodynamics and organ function. | ||
| Keywords | ||
| SEPTIC SHOCK; PNEUMONIA; β-blockers | ||
|
Supplementary Files
|
||
|
Statistics Article View: 5 |
||
